SCIENTIFIC AGENDA

THURSDAY, DECEMBER 1, 2005
7:00 am
Breakfast

8:00 am
Welcome and introduction
Stephen B. Hanauer, MD and
Richard P. MacDermott, MD

Session I: Advances in basic science in IBD
Co-chairs: Richard S. Blumberg, MD and Lloyd F. Mayer, MD
8:10 am
Genetics of IBD
John Rioux, PhD

8:30 am
Bacteria in IBD
R. Balfour Sartor, MD

8:50 am
Animal models of IBD
Charles O. Elson III, MD

9:10 am
Innate immunity in IBD
Jonathan Braun, MD

9:30 am
Panel discussion

10:00 am
Coffee break and poster viewing

Session II: Advances in basic research in IBD
Co-Chairs: Jonathan Braun, MD and Charles O. Elson III, MD
10:30 am
Epithelial cells in IBD
Lloyd F. Mayer, MD

10:50 am
Adaptive immunity in IBD
Richard S. Blumberg, MD

11:10 am
Cytokines in IBD
Theresa T. Pizzaro, MD

11:30 am
Healing the intestinal epithelium and mucosa
Jerrold R. Turner, MD

11:50 am
Panel discussion

12:20 pm
Lunch break

Session III: Plenary research session
Co-Chairs: Richard S. Blumberg, MD and Jonathan Braun, MD
1:50 pm
Presentation of research papers

3:20 pm
Adjourn

FRIDAY, DECEMBER 2, 2005
Session IV: Breakfast meeting
7:00 am
Breakfast presentations

Concurrent Session
Session Va: Advances in current therapy of IBD
Co-Chairs: Maria T. Abreu, MD and Kim L. Isaacs, MD
8:00 am
Approaches to mild to moderate
ulcerative colitis
Gary R. Lichtenstein, MD

8:20 am
First line approaches to Crohn’s Disease
William J. Sandborn, MD

8:40 am
Optimizing immunomodulators
Marla C. Dubinsky, MD

9:00 am
Positioning biologic therapy in IBD
Stephen B. Hanauer, MD

9:20 am
Panel discussion

9:40 am
Coffee break and poster viewing

Concurrent Session
Session Vb: Basic and clinical research session
Co-Chairs: Charles O. Elson III, MD and R. Balfour Sartor, MD
8:00 am
Presentation of research papers

9:40 am
Coffee break and poster viewing

Session VI: Advances in IBD
Co-Chairs: Gary R. Lichtenstein, MD and Bruce E. Sands, MD
10:10 am
Pharmacoeconomics of IBD therapy
Russell D. Cohen, MD

10:30 am
Advances in imaging of IBD
Edward V. Loftus Jr., MD

10:50 am
Capsule endoscopy in IBD
Asher A. Kornbluth, MD

11:10 am
Biomarkers in IBD
Maria T. Abreu, MD

11:30 am
Panel discussion

12:30 pm
Luncheon Symposium
Supported by Centocor, Inc.

Session VII: Debates 1: Controversies in IBD
Co-Chairs: Asher A. Kornbluth, MD and William J. Tremaine, MD
2:00 pm
Pro: There is good evidence that biologics are appropriate as first line therapy for Crohn’s Disease
Stephen B. Hanauer, MD

2:20 pm
Con: There is no good evidence that biologics are appropriate as first line therapy for Crohn’s Disease
Daniel H. Present, MD

2:40 pm
Panel discussion

3:00 pm
Pro: Long-standing ulcerative colitis patients with low-grade dysplasia and/or polyps should have colectomy
Thomas Ullman, MD

3:20 pm
Con: Long-standing ulcerative colitis patients with low-grade dysplasia and/or polyps should have polypectomy and surveillance colonoscopy
Russell D. Cohen, MD

3:40 pm
Panel discussion

4:00 pm
Coffee break and poster viewing

4:15 pm
Afternoon Symposium Supported by UCB Pharma, Inc.
Reception to follow

SATURDAY, DECEMBER 3, 2005
Session VIII: Breakfast meeting
7:00 am
Breakfast Symposium
Supported by Shire US, Inc.

Session IX: Advances in the management of IBD
Co-Chairs: Marla C. Dubinsky, MD and R. Balfour Sartor, MD
8:00 am
Prevention of post-operative recurrence of Crohn’s Disease
William J. Tremaine, MD

8:20 am
Use of genetic markers in IBD
David T. Rubin, MD

8:40 am
Deconstructing the Crohn’s Disease therapy pyramid
Bruce E. Sands, MD

9:00 am
Fertility issues in IBD
Kim L. Isaacs, MD

9:20 am
Panel discussion

9:30 am
Coffee break and poster viewing

Session X: Advances in new biologics
Co-Chairs: William J. Sandborn, MD and TBA
10:00 am
Strategies against Tcells/TNF/cytokines
Scott Plevy, MD

10:20 am
Strategies against adhesion molecules
Brian G. Feagan, MD

10:40 am
Strategies to induce apoptosis
Ivan J. Fuss, MD

11:00 am
Strategies toward T regulatory cells in IBD treatment
Casey T. Weaver, MD

11:20 am
Panel discussion

11:40 am
Luncheon Symposium
Supported by Procter and Gamble Pharmaceuticals

Session XI: Debates 2: Controversies in IBD
Co-Chairs: Russell D. Cohen, MD and William J. Tremaine, MD
1:30 pm
Pro: Chromoendoscopy should be the standard of care for surveillance in ulcerative colitis
Bret A. Lashner, MD

1:50 pm
Con: Chromoendoscopy should not be the standard of care for surveillance in ulcerative colitis
Charles N. Bernstein, MD

2:10 pm
Panel discussion

2:30 pm
Pro: The only way to classify IBD will be clinical phenotype
Asher A. Kornbluth, MD

2:50 pm
Con: The only way to classify IBD is to use serologic and genetic markers
Maria T. Abreu, MD

3:10 pm
Panel discussion

3:30 pm
Adjourn